Kiora Pharmaceuticals
Salt Lake City
About Kiora Pharmaceuticals
Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $106.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2024)
- Ticker: nasdaq:KPRX
- Website: kiorapharma.com
- Phone: 7813983811
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/kiora-pharmaceuticals-69540 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.